Vinblastine (VLB), bleomycin (BLEO), cis‐diamminedichloroplatinum (DDP) in disseminated extragonadal germ cell tumors. A southwest oncology group study

Lynn G. Feun, Michael K. Samson, Ronald L. Stephens

Research output: Contribution to journalArticle

85 Scopus citations

Abstract

Nineteen patients considered to have metastatic primary extragonadal germ cell cancer were entered on a phase II chemotherapy study using as induction therapy a combination of vinblastine (VLB) 12 mg/m2 day 1, bleomycin (BLEO) 15 U/m2 i.v. or i.m. twice weekly, and cis-diamminedichloroplatinum (DDP) 15 mg/m2 days 1-5, with vinblastine and DDP repeated at 28-day intervals for 4 mth. All complete or partial responders were then placed on a maintenance regimen of vinblastine 12 mg/m2 alternating monthly with actinomycin-D 1.5 mg/m2 day 29, and chlorambucil, 10 mg/m2 P.O. days 32-37. There were three complete remissions (CR's), 6 partial remissions (PR's), and 2 stable disease. The response rate (CR's + PR's) was 56%; however, the mean duration of response was only 2 mth (range, 1-8 mth). Drug toxicity was significant and there was one toxic death. Unlike patients with disseminated testicular cancer, patients with primary metastatic extragonadal germ cell carcinoma appear to do less well on this particular drug regimen. Further investigation using different drug regimens seems necessary.

Original languageEnglish (US)
Pages (from-to)2543-2549
Number of pages7
JournalCancer
Volume45
Issue number10
DOIs
StatePublished - May 15 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Vinblastine (VLB), bleomycin (BLEO), cis‐diamminedichloroplatinum (DDP) in disseminated extragonadal germ cell tumors. A southwest oncology group study'. Together they form a unique fingerprint.

  • Cite this